Acquisition presentation
Logotype for Merck KGaA

Merck (MRK) Acquisition presentation summary

Event summary combining transcript, slides, and related documents.

Logotype for Merck KGaA

Acquisition presentation summary

12 Nov, 2026

Transaction and strategic rationale

  • All-cash proposal of $20 per Silence Therapeutics ADS, representing €0.9bn enterprise value; closing expected in Q1 2027, subject to relevant approvals.

  • Expected IRR exceeds WACC and supports Healthcare’s long-term mid-single-digit growth ambition.

  • Transaction supports rare-disease growth, replenishes Healthcare’s mid-stage pipeline and advances the Global Specialty Innovator strategy.

  • Strengthens oligonucleotide capabilities, with potential expansion in hematology-oncology and adjacent targeted specialty and rare diseases.

Divesiran opportunity and clinical evidence

  • Silence Therapeutics is a clinical-stage biotech focused on siRNA therapies; lead asset divesiran is pre-Phase III with best-in-class potential in polycythemia vera (PV), a rare chronic blood cancer.

  • PV has ~100k addressable patients in the US by company estimate; unmet need includes phlebotomy-free treatment and superior, durable hematocrit control.

  • Divesiran targets TMPRSS6 via GalNAc-conjugated siRNA, enhancing the hepcidin pathway; subcutaneous dosing supports Q12W administration.

  • Phase II primary endpoint met: 88% clinical response with divesiran vs 19% with placebo during weeks 18–36 (p<0.0001); placebo-adjusted response rate 69%.

  • Mean phlebotomies during weeks 0–36 were 0.2 with divesiran vs 2.1 with placebo (p<0.0001); results also showed improved hematocrit control, iron markers and reported quality of life.

  • Divesiran was generally well tolerated, with no new safety findings; Phase III initiation is supported for H1 2027, with potential upside in other iron-overload indications.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Merck